Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Leuk Res Retrieve available abstracts of 137 articles: HTML format

Single Articles

October 2025
1. CLAIBORNE JP, Li D, Tsai HL, Ghiaur G, et al
   Efficacy and safety of blinatumomab for CD19?+?acute leukemias in patients historically excluded from clinical trials due to comorbidities.
   Leuk Res. 2025;157:108098.
   PubMed     Abstract available
   
   
   September 2025
2. ATALLAH EL, Sadek I, Wei D, Latremouille-Viau D, et al
   Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia.
   Leuk Res. 2025 Sep 5:108089. doi: 10.1016/j.leukres.2025.108089.
   PubMed     Abstract available
   
   
   
3. MOLINA A, Khanna V, Jensen A, Stehr H, et al
   Molecular taxonomy of MDS/CMML patients influences responses to hypomethylating agents and clinical outcomes.
   Leuk Res. 2025;156:107736.
   PubMed     Abstract available
   
   
   August 2025
4. YANG Q, Ding Z, Liu Y, Chen S, et al
   Effect of sorafenib on prognosis in patients with low-allelic-ratio FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
   Leuk Res. 2025;157:108088.
   PubMed     Abstract available
   
   
   
5. RAVIPATI S, Bakheet W, Woldie I, Gupta R, et al
   Pilot study: A prospective, real-world, feasibility study testing a decreased frequency paradigm in treatment free remission in chronic myeloid leukemia.
   Leuk Res. 2025;157:108087.
   PubMed     Abstract available
   
   
   
6. ZHANG TY, Ge AY, Epstein MM, Patel SA, et al
   Treatment patterns and survival outcomes for very elderly patients with acute myeloid leukemia: A National Cancer Database study.
   Leuk Res. 2025;157:108086.
   PubMed     Abstract available
   
   
   
7. KELLAWAY SG
   Targeting growth signals in leukemia: A case of mistaken identity.
   Leuk Res. 2025;157:107935.
   PubMed    
   
   
   
8. FATHI AT, Smith BD, Angiolillo A, Binder G, et al
   Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial.
   Leuk Res. 2025;157:107925.
   PubMed    
   
   
   
9. JABBAN Y, He R, Bessonen K, Greipp P, et al
   Clinical characteristics and prognostic significance of co-mutated SETBP1/GATA2 myeloid neoplasms.
   Leuk Res. 2025;155:107734.
   PubMed     Abstract available
   
   
   July 2025
10. YANG X, Huang R
    Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapies.
    Leuk Res. 2025;157:107924.
    PubMed     Abstract available
    
    
    
11. LEI H, Xu H, Wang Y, Wu Y, et al
    CHK1-S, a splicing variant of CHK1, suppresses chronic myeloid leukemia.
    Leuk Res. 2025;156:107922.
    PubMed     Abstract available
    
    
    
12. MUDD TW, Diebold K, Parks K, Hardee M, et al
    Outcomes with intensive chemotherapy, compared to hypomethylating agent + venetoclax, in patients with intermediate and adverse risk acute myeloid leukemia.
    Leuk Res. 2025;156:107920.
    PubMed    
    
    
    
13. TARIQ H, Vadasz B, Gao J, Chen YH, et al
    Clinicopathologic, genetic, and prognostic characteristics of single-hit versus multi-hit TP53-mutated chronic lymphocytic leukemia in the era of novel therapies.
    Leuk Res. 2025;156:107911.
    PubMed     Abstract available
    
    
    
14. STEINER L, Kaur N, Jann JC, Fabarius A, et al
    Inter-modality variance of blast quantification in patients with myelodysplastic neoplasms (MDS) and its impact on risk stratification and overall survival.
    Leuk Res. 2025;154:107718.
    PubMed     Abstract available
    
    
    June 2025
15. NAKAMURA F, Nakamura Y, Sasaki K, Yamazaki I, et al
    HDAC inhibitors repress Tek and Angpt1 expression and proliferation in RUNX1-MECOM-type leukemia cells.
    Leuk Res. 2025;156:107738.
    PubMed     Abstract available
    
    
    
16. REN Z, Vanhooren J, De Moerloose B, Lammens T, et al
    Involvement of THBS1 in myeloid sarcoma of acute myeloid leukemia.
    Leuk Res. 2025;155:107737.
    PubMed    
    
    
    
17. WANG H, Han C, Gong B, Liu Y, et al
    Clinical features and treatment response to TKIs in chronic myeloid leukemia patients with atypical BCR::ABL1 transcripts.
    Leuk Res. 2025;155:107733.
    PubMed     Abstract available
    
    
    
18. AMIN MK, Khan MA, Khan FH, Zakir A, et al
    Impact of FLT3 inhibitors on the outcomes of FLT3-ITD mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysis.
    Leuk Res. 2025;155:107724.
    PubMed     Abstract available
    
    
    
19. CAVALLARO G, Salmoiraghi S, Cavagna R, Pavoni C, et al
    Clinical impact of tyrosine kinases related mutations in NPM1 mutated acute myeloid leukaemia: A report from the Northern Italy Leukaemia Group (NILG) multicentre randomized trial 02/06.
    Leuk Res. 2025;153:107702.
    PubMed     Abstract available
    
    
    May 2025
20. HASLINGER S, Schinnerl D, Konig M, Inthal A, et al
    Identification of a novel amplified PAX5::RBPMS fusion gene in pediatric B-cell acute lymphoblastic leukemia.
    Leuk Res. 2025;154:107722.
    PubMed    
    
    
    
21. HAMMAMI MB, Qasim A, Shah A, Zhang H, et al
    Cutaneous manifestations of large granular lymphocytic leukemia: A case report and systematic review.
    Leuk Res. 2025;154:107720.
    PubMed    
    
    
    
22. KATO T, Imaizumi Y, Miyazaki Y
    Treatment strategy for indolent adult T-cell leukemia-lymphoma.
    Leuk Res. 2025;155:107714.
    PubMed     Abstract available
    
    
    
23. JOHNSON-ANSAH H, Charbonnier A, Etienne G, Roy L, et al
    Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC.
    Leuk Res. 2025;154:107716.
    PubMed     Abstract available
    
    
    
24. SHICHIJO T, Yasunaga JI
    Stratagems of HTLV-1 for persistent infection and the resultant oncogenesis: Immune evasion and clonal expansion.
    Leuk Res. 2025;152:107680.
    PubMed     Abstract available
    
    
    April 2025
25. KONDO K, Najima Y, Sadato D, Hirama C, et al
    Pre-transplant blinatumomab and/or inotuzumab ozogamicin therapy for relapsed/refractory acute lymphoblastic and B/myeloid mixed phenotype acute leukemia in adults.
    Leuk Res. 2025;153:107704.
    PubMed     Abstract available
    
    
    
26. AUBREY BJ, Blonquist T, McMasters M, Hobbs G, et al
    A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation.
    Leuk Res. 2025;153:107693.
    PubMed     Abstract available
    
    
    
27. ZHANG W, Cui Y, Wu J, Chen Y, et al
    Incidence and risk factors of venous thromboembolism in patients with acute Leukemia: A systematic review and meta-analysis.
    Leuk Res. 2025;153:107694.
    PubMed     Abstract available
    
    
    
28. VARGAS LCZ, Ortiz-Ortiz J, Martinez YA, Viguri GEC, et al
    Identification of ZNF384 as a regulator of epigenome in leukemia.
    Leuk Res. 2025;153:107691.
    PubMed     Abstract available
    
    
    
29. HIBINO Y, Fujisawa S, Fujimaki K, Hagihara M, et al
    Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective study in real-world practice.
    Leuk Res. 2025;152:107689.
    PubMed     Abstract available
    
    
    
30. AL MALKI MM, Minden MD, Rich ES, Hill JE, et al
    Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study.
    Leuk Res. 2025;152:107690.
    PubMed     Abstract available
    
    
    March 2025
31. DHANGAR S, Shanmukhaiah C, Ghatanatti J, Sawant L, et al
    Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patients.
    Leuk Res. 2025;152:107679.
    PubMed     Abstract available
    
    
    February 2025
32. KOGURE Y, Kataoka K
    Clinical and therapeutic significance of genetic profiling in adult T-cell leukemia/lymphoma.
    Leuk Res. 2025;151:107676.
    PubMed     Abstract available
    
    
    
33. THUY VT, Viet NL, Nghia NT, Cangelosi G, et al
    The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis.
    Leuk Res. 2025;151:107673.
    PubMed     Abstract available
    
    
    
34. WU Q, Zhong L, Zhang G, Han L, et al
    Complementing therapeutic strategies for acute myeloid leukemia: Signaling pathways and targets of traditional Chinese medicine.
    Leuk Res. 2025;151:107672.
    PubMed     Abstract available
    
    
    
35. SHI S, Zhou Q, Zhao D, Zarif M, et al
    Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion.
    Leuk Res. 2025;151:107665.
    PubMed     Abstract available
    
    
    
36. MAHMOOD NH, Kadir DH
    Sparsity regularization enhances gene selection and leukemia subtype classification via logistic regression.
    Leuk Res. 2025;150:107663.
    PubMed     Abstract available
    
    
    
37. KOMROKJI Z, Ali NA, Xie Z, Chan O, et al
    Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML).
    Leuk Res. 2025;150:107662.
    PubMed     Abstract available
    
    
    January 2025
38. YOSHIDA N, Hida A, Sakata R
    Trends of changes in human T-cell leukemia virus type 1 epidemiology in Japan and globally.
    Leuk Res. 2025;150:107654.
    PubMed     Abstract available
    
    
    
39. YOSHIMITSU M
    Targeted antibody therapy as a treatment strategy for aggressive adult T-cell leukemia/lymphoma.
    Leuk Res. 2025;149:107653.
    PubMed     Abstract available
    
    
    
40. DENG A, Zhang F, Wang M, Jiang D, et al
    A novel KMT2A::DCP1A fusion gene in acute myeloid leukemia.
    Leuk Res. 2025;149:107645.
    PubMed    
    
    
    
41. EPSTEIN-PETERSON ZD, Gurumurthi A, Horwitz SM
    New treatments for adult T-cell leukemia/lymphoma.
    Leuk Res. 2025;149:107642.
    PubMed     Abstract available
    
    
    
42. FONTECHA MB, Del Rosario Anadon M, Lahitou IMM, Weich N, et al
    Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia.
    Leuk Res. 2025;149:107644.
    PubMed     Abstract available
    
    
    
43. WETERINGS DA, Rowan AG, Cook LB
    Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL).
    Leuk Res. 2025;148:107635.
    PubMed     Abstract available
    
    
    
44. WU H, Luo H, Wang M, Du Y, et al
    NAP1L5 promotes epithelial-mesenchymal transition by regulating PEG10 expression in acute myeloid leukaemia.
    Leuk Res. 2025;148:107623.
    PubMed     Abstract available
    
    
    December 2024
45. ZHAO R, Cui Y, Li D, Guo X, et al
    Anlotinib enhances the pro-apoptotic effect of APG-115 on acute myeloid leukemia cell lines by inhibiting the P13K/AKT signaling pathway.
    Leuk Res. 2024;149:107637.
    PubMed     Abstract available
    
    
    
46. SHAHZAD M, Iqbal Q, Amin MK, Irfan S, et al
    Outcomes of hematopoietic stem cell transplantation in primary plasma cell leukemia: A systematic review and meta-analysis.
    Leuk Res. 2024;148:107640.
    PubMed     Abstract available
    
    
    
47. LI M, Zhang S, Wei J, Liu M, et al
    The increase in the expression of circRNAs may contributes to a poor prognosis in acute myeloid leukemia: A systematic review and meta-analysis.
    Leuk Res. 2024;148:107639.
    PubMed     Abstract available
    
    
    
48. LI J, Fu S, Ye C, Li J, et al
    Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy.
    Leuk Res. 2024;148:107638.
    PubMed     Abstract available
    
    
    
49. KARUBE K, Sakihama S, Takatori M, Morichika K, et al
    Recent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era.
    Leuk Res. 2024;148:107634.
    PubMed     Abstract available
    
    
    
50. FUJI S
    Chemotherapy and allo-HSCT for young patients with aggressive ATL.
    Leuk Res. 2024;147:107596.
    PubMed     Abstract available
    
    
    November 2024
51. ROUZBAHANI M, Mousavi SA, Hajianfar G, Ghanaati A, et al
    Predictive modeling of outcomes in acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation using machine learning techniques.
    Leuk Res. 2024;148:107619.
    PubMed     Abstract available
    
    
    
52. KIM JY, Vijayakumar KA, Cho GW
    Exploring the impact of methylation aging on acute myeloid leukemia: Insights from the aging clock.
    Leuk Res. 2024;148:107620.
    PubMed     Abstract available
    
    
    
53. QIAN S, Gong J, Shen X, Chen M, et al
    Causal role of genetically predicted 731 immune cell phenotypes in chronic lymphatic leukemia: A bidirectional Mendelian randomization study.
    Leuk Res. 2024;148:107621.
    PubMed     Abstract available
    
    
    
54. WANG X, Chen T
    Diagnostic challenges and criteria application in a 70-year-old patient with oligo monocytic chronic granulomonocytic leukemia: A case report.
    Leuk Res. 2024;147:107616.
    PubMed    
    
    
    
55. MISHRA R, Calabrese C, Jain AG, Singh A, et al
    Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review.
    Leuk Res. 2024;146:107584.
    PubMed     Abstract available
    
    
    October 2024
56. ISFORT S, Gambacorti-Passerini C, Brummendorf TH, Smith BD, et al
    The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis.
    Leuk Res. 2024;147:107609.
    PubMed    
    
    
    
57. CHIEN KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, et al
    A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.
    Leuk Res. 2024;147:107602.
    PubMed    
    
    
    
58. EL HAJJ H, Hermine O, Bazarbachi A
    Therapeutic advances for the management of adult T cell leukemia: Where do we stand?
    Leuk Res. 2024;147:107598.
    PubMed     Abstract available
    
    
    
59. LI T, Cui Q, Liu S, Li Z, et al
    Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.
    Leuk Res. 2024;145:107569.
    PubMed     Abstract available
    
    
    September 2024
60. PRIYA, Garg M, Talwar R, Bharadwaj M, et al
    Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic review with meta-analysis.
    Leuk Res. 2024;147:107595.
    PubMed     Abstract available
    
    
    
61. CHEN R, AlHumaid M, Daher-Reyes G, Atenafu EG, et al
    Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience.
    Leuk Res. 2024;147:107586.
    PubMed     Abstract available
    
    
    
62. XIAO Y, Xiao L, Xu X, Guan X, et al
    Development and validation of a predictive model for tumor lysis syndrome in childhood acute lymphoblastic leukemia.
    Leuk Res. 2024;146:107587.
    PubMed     Abstract available
    
    
    
63. FAIZ AS, Guo S, Sridharan A, Lin Y, et al
    Risk factors and mortality associated with venous thromboembolism in the elderly US population with chronic lymphocytic leukemia.
    Leuk Res. 2024;146:107585.
    PubMed     Abstract available
    
    
    
64. ACHAR RK, McCormick BJ, Dworkin E, Geramita EM, et al
    Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy.
    Leuk Res. 2024;146:107577.
    PubMed    
    
    
    
65. WU S, Liu F, Gai Y, Carter J, et al
    Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML.
    Leuk Res. 2024;144:107547.
    PubMed     Abstract available
    
    
    August 2024
66. DESAI A, Samara Y, Yang D, Ball B, et al
    Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation.
    Leuk Res. 2024;145:107565.
    PubMed     Abstract available
    
    
    
67. DIAZ MARTINEZ JP, de Maraumont TA, Camacho LM, Garcia L, et al
    Cost-effectiveness of blinatumomab for the treatment of B?precursor acute lymphoblastic leukemia pediatric patients with high?risk first?relapse in Mexico.
    Leuk Res. 2024;145:107560.
    PubMed     Abstract available
    
    
    
68. CINGELOVA S, Mikuskova E, Demitrovicova L, Mikudova V, et al
    Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide.
    Leuk Res. 2024;145:107567.
    PubMed     Abstract available
    
    
    
69. FU Q, Wang Y, Liu H, Gao H, et al
    Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3(mut) acute myeloid leukemia.
    Leuk Res. 2024;145:107564.
    PubMed     Abstract available
    
    
    
70. TRAVAGLINI S, Silvestrini G, Attardi E, Fanciulli M, et al
    Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia.
    Leuk Res. 2024;145:107568.
    PubMed     Abstract available
    
    
    
71. SHIMIZU H, Kato J, Tanoue S, Kimura SI, et al
    Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols.
    Leuk Res. 2024;144:107562.
    PubMed     Abstract available
    
    
    
72. BOISCLAIR S, Zhou E, Naing P, Thakur R, et al
    Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML.
    Leuk Res. 2024;143:107545.
    PubMed     Abstract available
    
    
    
73. GALIENI P, Troiani E, Picardi P, Angelini M, et al
    Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT).
    Leuk Res. 2024;143:107541.
    PubMed     Abstract available
    
    
    
74. EDWARDS K, Manoussaka M, Sayed U, Tsertsvadze T, et al
    MD-1 downregulation is associated with reduced cell surface CD180 expression in CLL.
    Leuk Res. 2024;143:107540.
    PubMed     Abstract available
    
    
    
75. VIANNA DT, Reis Monte-Mor BDC, Noronha EP, Gutiyama LM, et al
    Molecular characterization of V(D)J rearrangements in immature acute leukemias.
    Leuk Res. 2024;143:107521.
    PubMed     Abstract available
    
    
    July 2024
76. CUI H, Ma Y, Han S, Zhang X, et al
    Arsenic trioxide regulates the glycolytic pathway to treat acute promyelocytic leukemia by inhibiting RPL22L1.
    Leuk Res. 2024;144:107550.
    PubMed     Abstract available
    
    
    
77. MOLICA M, Perrone S, Rossi M, Giannarelli D, et al
    The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis.
    Leuk Res. 2024;144:107549.
    PubMed     Abstract available
    
    
    
78. KONG C, Wu M, Lu Q, Ke B, et al
    PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia.
    Leuk Res. 2024;144:107548.
    PubMed     Abstract available
    
    
    
79. MESTRUM SGC, Roanalis BYV, de Wit NCJ, Drent RJM, et al
    MDS and AML show elevated fractions of CD34-positive blast cell populations with a high anti-apoptotic versus proliferation ratio.
    Leuk Res. 2024;142:107520.
    PubMed     Abstract available
    
    
    June 2024
80. PARMAR K, Kundu R, Maiti A, Ball S, et al
    Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia.
    Leuk Res. 2024;144:107546.
    PubMed     Abstract available
    
    
    
81. XU Z, Zhang T, Hao J, Liu D, et al
    Identification of clonal relationship and prognostic significance in acute myeloid leukemia patients with concomitant increase in mast cells.
    Leuk Res. 2024;143:107539.
    PubMed    
    
    
    
82. SHIN DY, Park S, Jang E, Kong JH, et al
    Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials.
    Leuk Res. 2024;143:107542.
    PubMed     Abstract available
    
    
    
83. JESTRABEK H, Kohlhas V, Hallek M, Nguyen PH, et al
    Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia.
    Leuk Res. 2024;143:107531.
    PubMed     Abstract available
    
    
    
84. PANDA T, Rainchwar S, Singh R, Singh A, et al
    Real world outcome of B ALL with t (1; 19) (q23; p13)/TCF3::PBX1 in adolescents and adults treated with intensive regimes.
    Leuk Res. 2024;141:107506.
    PubMed     Abstract available
    
    
    May 2024
85. ODUTOLA PO, Olorunyomi PO, Olorunyomi I
    Single vs double umbilical cord blood transplantation in acute leukemia: Systematic review and meta-analysis.
    Leuk Res. 2024;142:107517.
    PubMed     Abstract available
    
    
    
86. RISUENO A, See WL, Bluemmert I, de Botton S, et al
    Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
    Leuk Res. 2024;140:107497.
    PubMed     Abstract available
    
    
    April 2024
87. SUN M, Li S, Liu Z, Ma S, et al
    Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation.
    Leuk Res. 2024;142:107507.
    PubMed     Abstract available
    
    
    
88. INDRAN T, Das T, Muirhead J, O'Brien M, et al
    Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34(+) and CD3(+) donor chim
    Leuk Res. 2024;142:107504.
    PubMed     Abstract available
    
    
    
89. MOHEBBI A, Shahriyary F, Farrokhi V, Bandar B, et al
    A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2024;141:107505.
    PubMed     Abstract available
    
    
    
90. ZAD Z, Bonecker S, Wang T, Zalcberg I, et al
    Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models.
    Leuk Res. 2024;141:107502.
    PubMed    
    
    
    
91. BERTON G, Sedaki B, Collomb E, Benachour S, et al
    Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.
    Leuk Res. 2024;141:107500.
    PubMed     Abstract available
    
    
    
92. DONG S, Premnath N, Sadeghi N, Kainthla R, et al
    Racial and ethnic disparities in Acute Myeloid Leukemia: 15-year experience at a safety net hospital system.
    Leuk Res. 2024;141:107503.
    PubMed     Abstract available
    
    
    
93. ASHOURI K, Ginosyan AA, Chu M, Hom B, et al
    Donor matters: Donor selection impact on hematopoietic stem cell transplantation outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights from a myeloablative HSCT study.
    Leuk Res. 2024;141:107501.
    PubMed     Abstract available
    
    
    
94. HU X, Cao P, Wang F, Wang T, et al
    Alternative polyadenylation quantitative trait loci contribute to acute myeloid leukemia risk genes regulation.
    Leuk Res. 2024;141:107499.
    PubMed     Abstract available
    
    
    
95. SMITH BD, Brummendorf TH, Roboz GJ, Gambacorti-Passerini C, et al
    Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
    Leuk Res. 2024;139:107481.
    PubMed     Abstract available
    
    
    
96. MORSY MM, Azzam AY, Elamin O, Elswedy A, et al
    Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis.
    Leuk Res. 2024;140:107498.
    PubMed     Abstract available
    
    
    March 2024
97. YIGIT KAYA S, Mutlu YG, Malkan UY, Mehtap O, et al
    Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
    Leuk Res. 2024;140:107495.
    PubMed     Abstract available
    
    
    
98. MUTHIAH C, Narra R, Atallah E, Juan W, et al
    Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.
    Leuk Res. 2024;140:107496.
    PubMed     Abstract available
    
    
    
99. BRUNETTI M, Iasenza IA, Jenner AL, Raynal NJ, et al
    Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia.
    Leuk Res. 2024;140:107485.
    PubMed     Abstract available
    
    
    
100. IKOMA-COLTURATO MRV, Severino AR, Dos Santos Tosi JF, Bertolucci CM, et al
     Clinical validation of a 10-color flow cytometry panel to detect measurable residual disease in acute myeloid leukemia.
     Leuk Res. 2024;140:107482.
     PubMed    
     
     
     
101. GARCIA-MANERO G, Kazmierczak M, Wierzbowska A, Fong CY, et al
     Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
     Leuk Res. 2024 Mar 12:107480. doi: 10.1016/j.leukres.2024.107480.
     PubMed     Abstract available
     
     
     
102. WAN CL, Huang YH, Huang SM, Xu YL, et al
     Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.
     Leuk Res. 2024;139:107483.
     PubMed     Abstract available
     
     
     
103. PAN L, Li Y, Gao H, Lai X, et al
     Clinical features and management of germline CEBPA-mutated carriers.
     Leuk Res. 2024;138:107453.
     PubMed     Abstract available
     
     
     
104. SIDI Y, Dong C, Wu Y, Faller DV, et al
     A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
     Leuk Res. 2024;138:107465.
     PubMed     Abstract available
     
     
     February 2024
105. BOURNE G, Diebold K, Espinoza-Gutarra M, Al-Kadhimi Z, et al
     Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
     Leuk Res. 2024;139:107467.
     PubMed     Abstract available
     
     
     
106. ZHONG S, Kurish H, Walchack R, Li H, et al
     Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia.
     Leuk Res. 2024;139:107468.
     PubMed     Abstract available
     
     
     
107. OSMAN AEG, Rets A, Patel AB
     KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia.
     Leuk Res. 2024;138:107466.
     PubMed    
     
     
     
108. SANCHEZ-PETITTO G, Goloubeva OG, Masur J, Childress J, et al
     Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
     Leuk Res. 2024;138:107456.
     PubMed     Abstract available
     
     
     
109. SUDO H, Tonoyama Y, Ikebe E, Hasegawa H, et al
     Proteomic analysis of adult T-cell leukemia/lymphoma: A biomarker identification strategy based on preparation and in-solution digestion methods of total proteins.
     Leuk Res. 2024;138:107454.
     PubMed     Abstract available
     
     
     
110. GOULART H, Sastow D, Moshier E, Martin L, et al
     Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement.
     Leuk Res. 2024;137:107452.
     PubMed     Abstract available
     
     
     
111. ELGHETANY MT, Patnaik MM, Khoury JD
     Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope.
     Leuk Res. 2024;137:107441.
     PubMed     Abstract available
     
     
     
112. RAMOS-CILLAN S, Lainez-Gonzalez D, Solan L, Blas C, et al
     When the devil is in the details: Similarities and differences between WHO and ICC classifications of AML.
     Leuk Res. 2024;137:107440.
     PubMed    
     
     
     January 2024
113. BOUCHER L, Rozalska L, Sorel N, Olivier G, et al
     Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
     Leuk Res. 2024;137:107439.
     PubMed    
     
     
     
114. OH I, Hatano K, Ikeda T, Toda Y, et al
     Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults.
     Leuk Res. 2024;137:107438.
     PubMed    
     
     
     
115. DIDI I, Alliot JM, Dumas PY, Vergez F, et al
     Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
     Leuk Res. 2024;136:107437.
     PubMed     Abstract available
     
     
     
116. KLINK AJ, Gajra A, Knoth RL, Marshall L, et al
     Corrigendum to "Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia" [Leuk. Res. (2022) 106946].
     Leuk Res. 2024 Jan 9:107430. doi: 10.1016/j.leukres.2023.107430.
     PubMed    
     
     
     
117. KUSNE Y, Lasho T, Finke C, Patnaik MM, et al
     VEXAS syndrome in a patient with DDX41 germline predisposition syndrome.
     Leuk Res. 2024;136:107432.
     PubMed    
     
     
     
118. KHANNA V, Lu R, Kumar J, Molina A, et al
     The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
     Leuk Res. 2024;136:107433.
     PubMed     Abstract available
     
     
     December 2023
119. NOTARANTONIO AB, Roth-Guepin G, Bonmati C, Divoux M, et al
     A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes.
     Leuk Res. 2023;135:107405.
     PubMed    
     
     
     November 2023
120. ASHBY M, Fleming S, Teh TC, Tiong IS, et al
     Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy.
     Leuk Res. 2023;136:107429.
     PubMed    
     
     
     
121. URBINO I, Secreto C, Apolito V, Olivi M, et al
     Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.
     Leuk Res. 2023 Nov 18:107421. doi: 10.1016/j.leukres.2023.107421.
     PubMed    
     
     
     
122. ZHAO D, Zhou Q, Zarif M, Eladl E, et al
     AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
     Leuk Res. 2023;134:107376.
     PubMed     Abstract available
     
     
     October 2023
123. RAVINDRA A, Acharya L, Loeffler B, Mott S, et al
     Venetoclax-based therapy in treatment-naive and relapsed/refractory acute myeloid leukemia.
     Leuk Res. 2023;135:107407.
     PubMed     Abstract available
     
     
     
124. ANSARI F, Behfar M, Jafari L, Mohseni R, et al
     A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis.
     Leuk Res. 2023;135:107416.
     PubMed     Abstract available
     
     
     
125. ZHANG F, Du H, Hu C, Song Y, et al
     A new prognostic risk model for acute myeloid leukemia patients based on telomere-related genes.
     Leuk Res. 2023;135:107404.
     PubMed     Abstract available
     
     
     
126. SHERBAN A, Fredman D, Shimony S, Yeshurun M, et al
     Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review.
     Leuk Res. 2023;133:107368.
     PubMed     Abstract available
     
     
     September 2023
127. JIMENEZ-VICENTE C, Martinez-Roca A, Pomares H, Castano-Diez S, et al
     Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.
     Leuk Res. 2023;135:107403.
     PubMed    
     
     
     
128. JAMY OH, Kasner M, Wall S, Ingram S, et al
     Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions.
     Leuk Res. 2023;134:107393.
     PubMed     Abstract available
     
     
     
129. GURNEY M, Greipp PT, Gliem T, Knudson R, et al
     TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.
     Leuk Res. 2023;134:107391.
     PubMed    
     
     
     
130. SINGH C, Karunakaran P, Yanamandra U, Jindal N, et al
     Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid.
     Leuk Res. 2023;134:107392.
     PubMed     Abstract available
     
     
     
131. PATEL SA, Bello E, Wilks A, Gerber JM, et al
     Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.
     Leuk Res. 2023;134:107388.
     PubMed     Abstract available
     
     
     
132. HIRT CK, Padmanabha N, Michaels PD
     Cohesin complex mutations in myeloid neoplasms are enriched for SRSF2, RUNX1, TET2, and NRAS co-mutations and morphologic dysplasia.
     Leuk Res. 2023;132:107357.
     PubMed    
     
     
     
133. BRANDWEIN JM, Ebeling K, Ding L, Liew E, et al
     Changing frontline AML treatment patterns from 2013 to 2022.
     Leuk Res. 2023;132:107354.
     PubMed     Abstract available
     
     
     
134. XIE W, Wang Z, Guo X, Guan H, et al
     MiR-409-3p regulates the proliferation and apoptosis of THP-1 through targeting Rab10.
     Leuk Res. 2023;132:107350.
     PubMed     Abstract available
     
     
     August 2023
135. KHADADAH FM, Cerquozzi S, Olney HJ, Fraga C, et al
     Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
     Leuk Res. 2023;133:107374.
     PubMed     Abstract available
     
     
     
136. BOULIGNY IM, Murray G, Ho T, Doyel M, et al
     Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
     Leuk Res. 2023;134:107370.
     PubMed    
     
     
     
137. ZHAO ZY, Tang N, Lin LE
     A rare BCR-ABL1 transcript in chronic myeloid leukemia: Case report and literature review.
     Leuk Res. 2023;133:107369.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.